Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Brimonidine tartrate + timolol maleate is a fixed-dose combination ophthalmic solution used to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension who require adjunctive or replacement therapy. The medication combines two active ingredients with complementary mechanisms of action. Brimonidine is an alpha-2 adrenergic receptor agonist that decreases aqueous humor production and increases uveoscleral outflow, thereby lowering IOP. Timolol is a non-selective beta-adrenergic receptor antagonist (beta blocker) that reduces aqueous humor production in the ciliary body, also resulting in decreased IOP. This combination provides additive effects for lowering eye pressure and is typically administered as one drop to the affected eye(s) twice daily[1][2][5][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on brimonidine tartrate + timolol maleate.